Larazotide Acetate

What Is Larazotide Acetate?

Larazotide acetate is a synthetic eight-amino-acid peptide, discovered through research into a bacterial toxin produced by Vibrio cholerae that affects the seals between intestinal cells, called tight junctions. It was developed as a tight junction regulator, designed to act locally in the gut rather than being absorbed systemically, with the goal of helping the intestinal barrier stay properly sealed.

The research rationale centers on celiac disease, where exposure to gluten triggers the release of a protein called zonulin, which opens tight junctions and allows immunogenic gluten fragments to cross into deeper gut tissue and trigger an immune reaction. Larazotide was designed to block this zonulin-driven opening, intended as an add-on to a gluten-free diet rather than a replacement for it.

What Larazotide Acetate Is Being Researched For

• Persistent Symptoms Despite a Gluten-Free Diet

  A randomized controlled trial in celiac disease patients with ongoing symptoms despite following a gluten-free diet found that Larazotide acetate improved symptom scores compared to placebo, though results across different measures were mixed.^[1]

• Tight Junction Regulation Mechanism

  Broader research has characterized exactly how Larazotide interacts with the zonulin pathway and tight junction proteins, providing the mechanistic foundation for its celiac disease research.^[2]

• The Phase 3 Trial Outcome

  Larazotide reached Phase 3 development, the most advanced stage of any compound covered on this site apart from approved drugs, and received FDA Fast Track designation. However, the Phase 3 CeDLara trial did not meet its primary endpoint in 2022, an outcome that's essential context for understanding the current state of this research.

How Larazotide Acetate Works

• Blocking Zonulin-Driven Tight Junction Opening

  Research points to Larazotide acting as a zonulin antagonist, competing with zonulin for receptor binding and reducing the signaling cascade that would otherwise disassemble tight junction proteins in response to gluten exposure.^[2]

• Supporting Tight Junction Reassembly

  Research points to Larazotide promoting the rearrangement of actin filaments and tight junction proteins to help restore barrier function, including evidence that it inhibits an enzyme called myosin light chain kinase, reducing tension on the cell structures that would otherwise pull tight junctions open.^[2]

• A Locally-Acting, Non-Absorbed Peptide

  Research points to Larazotide working within the gut itself rather than being absorbed into the bloodstream, which is part of its intended safety profile as an oral, gut-restricted therapy.

Reconstitution and Handling

Larazotide acetate is typically supplied as a lyophilized powder in a sealed vial and reconstituted with bacteriostatic water before use in a research setting. Water should be added slowly rather than injected directly into the powder, and the vial should be swirled, not shaken.

Since the amount of water used affects the concentration of the final solution, researchers often use a dosage calculator to work this out before mixing. Once reconstituted, the solution is kept refrigerated to help preserve its stability.

Key Takeaways

Larazotide acetate represents one of the more clinically advanced compounds on this site, having reached Phase 3 trials with FDA Fast Track designation, but its research record is honestly mixed: Phase 2 signals were promising, while the pivotal Phase 3 trial did not meet its primary endpoint. Its mechanism, blocking zonulin-driven tight junction opening, remains well-characterized at the cell and tissue level, even as the clinical outcome data has been less conclusive than earlier results suggested.

Frequently Asked Questions

Sources and Research

1. Leffler DA, Kelly CP, Green PH, et al. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. Gastroenterology. 2015;148(7):1311-1319.
2. Khaleghi S, Ju JM, Lamba A, Murray JA. The potential utility of tight junction regulation in celiac disease: focus on larazotide acetate. Therap Adv Gastroenterol. 2016;9(1):37-49.